Core Viewpoint - The company, Magmi Tech, announced on October 15, 2025, that it will continue to utilize part of its idle raised funds for cash management to improve the efficiency of fund usage while ensuring project funding needs are met [1] Group 1: Cash Management of Idle Funds - The company has set a cash management limit of no more than 100 million yuan for idle funds from the 2019 convertible bonds and 300 million yuan for the 2022 convertible bonds, with a maximum term of 12 months [1] - The company has successfully redeemed investments made with idle funds, including a total of 2 million yuan invested in structured deposits with Shanghai Pudong Development Bank, yielding a return of 97,111.11 yuan by October 9, 2025 [2] - Another 2 million yuan was invested in a different structured deposit with the same bank, yielding a return of 32,222.22 yuan by the announcement date [2] Group 2: 2019 Convertible Bonds Cash Management - The company issued a total of 655 million yuan in convertible bonds in 2019, and has utilized idle funds for cash management, achieving a total return of 872,333.33 yuan from a rolling amount of 60 million yuan over the past twelve months [4] - The cash management products included a structured deposit with a guaranteed principal and an expected annual yield of 0.7% to 2.35% [2] Group 3: 2022 Convertible Bonds Cash Management - In 2022, the company issued convertible bonds totaling 1.22 billion yuan, with cash management activities yielding a total return of 1,556,153.37 yuan from a rolling amount of 213 million yuan [4] - The cash management products included a one-year CD with an expected annual yield of 1.70% and a six-month CD with an expected yield of 1.35% [3] Group 4: Risk Management and Company Impact - The company has implemented several risk control measures for its cash management activities, including financial department evaluations and independent oversight by directors and supervisors [4] - The use of idle funds for low-risk financial products is expected to enhance fund efficiency and asset returns without affecting the cash flow for project investments [4]

Core Viewpoint - Beisen Holdings (09669) announced a subscription to a wealth management product from Bank of China for an amount of RMB 100 million, which is part of a total outstanding principal of RMB 360 million related to such subscriptions as of the announcement date [1] Group 1 - The subscription provides a higher return compared to typical fixed deposits offered by commercial banks in China [1] - The principal for the subscription is based on the company's temporarily idle funds [1] - The funds for the subscription are drawn from the company's surplus cash reserves rather than proceeds from global offerings, ensuring no impact on the company's operating capital or operations [1] - Engaging in low-risk appropriate wealth management is beneficial for the company to enhance capital utilization and increase income from idle funds [1]

Core Viewpoint - Beisen Holdings (09669) has announced a subscription to a wealth management product from Bank of China amounting to RMB 100 million, which is part of a total outstanding principal of RMB 360 million in subscriptions with the bank [1] Group 1: Financial Details - The subscription is expected to provide higher returns compared to regular fixed deposits offered by commercial banks in China [1] - The principal for the subscription is based on the company's temporarily idle funds [1] - The funds for the subscription are drawn from the company's surplus cash reserves rather than proceeds from global offerings, ensuring no impact on the company's operating capital [1] Group 2: Strategic Implications - The low-risk nature of the wealth management product is seen as beneficial for enhancing capital utilization and increasing income from idle funds [1]

Core Viewpoint - The company, Chaoyu Eye Care (02219), announced that its indirect wholly-owned subsidiary, Chaoyu Medical Technology, will further subscribe to a financial product from the Bank of China with a total principal amount of RMB 240 million, scheduled for September 26, 2025 [1] Group 1 - The total principal amount of the financial product subscription is RMB 240 million [1]

Group 1 - The company, Chaoyou Eye Care (02219), announced that its indirect wholly-owned subsidiary, Chaoyou Medical Technology, will further subscribe to a financial product from the Bank of China with a total principal amount of RMB 240 million by September 26, 2025 [1]

Group 1 - The company, Chaoyu Eye Care (02219.HK), announced a further subscription of RMB 240 million in wealth management products from the Bank of China, scheduled for September 26, 2025 [1] - The subscription will be funded by the group's surplus cash rather than proceeds from a global offering [1]

Core Viewpoint - The company, Chaoyu Eye Care (02219), announced that its indirect wholly-owned subsidiary, Chaoyu Medical Technology, will further subscribe to a financial product from the Bank of China with a total principal amount of RMB 30 million, funded by the group's surplus cash rather than proceeds from a global offering [1] Group 1 - The subscription amount for the financial product is RMB 30 million [1] - The funding for this subscription comes from the company's surplus cash [1] - The subscription is scheduled for August 22, 2025 [1]

Group 1 - The company, Chaoyu Eye Care (02219), announced that on August 22, 2025, its indirect wholly-owned subsidiary, Chaoyu Medical Technology, will further subscribe to a financial product from the Bank of China with a total principal amount of RMB 30 million [1] - The subscription will be funded by the group's surplus cash rather than proceeds from a global offering [1]

Group 1 - The core point of the article is that Chaogu Medical Technology, a wholly-owned subsidiary of Chaogu Eye Care, has further subscribed to a financial product from the Bank of China with a total principal amount of RMB 30 million, effective August 22, 2025 [1]